Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status

BACKGROUND: Neoadjuvant erlotinib and customized adjuvant therapy are appealing but controversial. The purpose of this study was to evaluate the role of biomarker-guided neoadjuvant treatment strategy in patients with IIIA-N2 non-small cell lung cancer (NSCLC) stratified by epidermal growth factor r...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhong, Wenzhao, Yang, Xuening, Yan, Honghong, Zhang, Xuchao, Su, Jian, Chen, Zhihong, Liao, Riqiang, Nie, Qiang, Dong, Song, Zhou, Qing, Yang, Jinji, Tu, Haiyan, Wu, Yi-Long
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4455050/
https://www.ncbi.nlm.nih.gov/pubmed/25981169
http://dx.doi.org/10.1186/s13045-015-0151-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4455050/
https://www.ncbi.nlm.nih.gov/pubmed/25981169
http://dx.doi.org/10.1186/s13045-015-0151-3

Ejemplares similares